Ginkgo Investor Conference Presentation Deck
Titer (Normalized to Positive Control)
Promoter
RBS
Tag
Strain
D1 subunit
backbone
D12 subunit
Tag
Ginkgo screened 100s of expression constructs for VCE and employed
a tagging strategy to inform screening, solubility, stability, and
purification. The library varied promoters, ribozymes, RBS', recodes,
and backbones, while the VCE sequence was retained. Process
improvements by Ginkgo leveraging small-scale lab fermentation
yielded further improvements and were followed by a successful tech
transfer to the partner. Project took 14 months from start in Ginkgo's
foundry to announcement of successful scale-up by the customer.
Tom Foti, President of the
Protein Business Unit at
Aldevron
"Since announcing our
manufacturing breakthrough on
VCE, we're excited to share that
we have produced and released
product conforming to ISO13485
quality standards, and expect to
release VCE under CGMP
manufacturing in 2022. We are
servicing a dozen or more clients
with increased manufacturing
scales coming on-line in 2022 and
beyond."
15
Property of Ginkgo Bioworks
J.P. MORGAN HEALTHCARE CONFERENCE 2022View entire presentation